Biontech announces first patient dosed in phase 2 clinical trial of mrna-based bnt111 in patients with advanced melanoma

Mainz, germany, june 18, 2021 (globe newswire) – biontech se (nasdaq: bntx, “biontech” or “the company”), announced today that the first patient has been treated in its bnt111 phase 2 cancer vaccine trial ( 2020-002195-12 ; nct04526899 ). the study is evaluating the company's therapeutic cancer vaccine candidate bnt111 in combination with libtayo® (cemiplimab) in patients with anti-pd1-refractory/relapsed unresectable stage iii or iv melanoma. bnt111 is the lead product candidate from biontech's fixvac platform that targets a fixed combination of mrna-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer and is fully owned by biontech.
BNTX Ratings Summary
BNTX Quant Ranking